PROTAGONIST THERAPEUTICS INC's ticker is PTGX and the CUSIP is 74366E102. A total of 157 filers reported holding PROTAGONIST THERAPEUTICS INC in Q4 2023. The put-call ratio across all filers is 0.17 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $12,818,942 | +32.1% | 369,955 | +10.3% | 0.00% | +33.3% |
| Q1 2024 | $9,700,751 | +46.3% | 335,318 | +16.0% | 0.00% | 0.0% |
| Q4 2023 | $6,628,582 | +459.2% | 289,079 | +306.8% | 0.00% | +200.0% |
| Q3 2023 | $1,185,264 | -20.4% | 71,059 | +9.7% | 0.00% | 0.0% |
| Q2 2023 | $1,489,894 | 0.0% | 64,778 | 0.0% | 0.00% | 0.0% |
| Q1 2023 | $1,489,894 | -99.4% | 64,778 | +137.5% | 0.00% | – |
| Q3 2022 | $229,928,000 | -11.0% | 27,275 | -16.5% | 0.00% | – |
| Q2 2022 | $258,372,000 | -66.6% | 32,664 | 0.0% | 0.00% | – |
| Q1 2022 | $773,483,000 | -30.8% | 32,664 | 0.0% | 0.00% | – |
| Q4 2021 | $1,117,109,000 | +128.4% | 32,664 | +18.4% | 0.00% | – |
| Q3 2021 | $489,037,000 | -60.5% | 27,598 | 0.0% | 0.00% | -100.0% |
| Q2 2021 | $1,238,598,000 | +91.3% | 27,598 | +10.4% | 0.00% | – |
| Q1 2021 | $647,500,000 | +163.3% | 25,000 | +104.9% | 0.00% | – |
| Q4 2020 | $245,952,000 | – | 12,200 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Johnson & Johnson Innovation - JJDC, Inc. | 2,449,183 | $43,253,000 | 8.50% |
| BVF INC/IL | 2,367,288 | $41,806,000 | 2.58% |
| RTW INVESTMENTS, LP | 3,383,208 | $59,747,000 | 1.68% |
| Novo Holdings A/S | 824,169 | $14,555,000 | 0.94% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 1,013,495 | $17,898,000 | 0.52% |
| Sofinnova Investments, Inc. | 326,064 | $5,758,000 | 0.36% |
| FARALLON CAPITAL MANAGEMENT LLC | 2,500,000 | $44,150,000 | 0.35% |
| Virtus ETF Advisers LLC | 21,639 | $382,000 | 0.18% |
| Baker Brothers Advisors | 1,911,446 | $33,756,000 | 0.15% |
| King Wealth Management Group | 22,000 | $389,000 | 0.11% |